NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT06169124 2026-04-13
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT07344779 2026-04-03
ROAD
Bayer
Active not recruiting
NCT05059236 2026-04-02
ARASEC
Bayer
Phase 2 Active not recruiting
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04484818 2026-03-23
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05794906 2026-03-17
ARASTEP
Bayer
Phase 3 Active not recruiting
NCT06463457 2026-03-09
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05683964 2026-02-13
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
Phase EARLY_PHASE1 Active not recruiting
NCT04558866 2026-02-12
ExBAT
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06627530 2026-02-11
COAction
Brazilian Clinical Research Institute
Phase 4 Active not recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT05367440 2025-12-08
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT05669664 2025-11-10
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02972060 2025-09-19
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT04136353 2023-07-28
DASL-HiCaP
University of Sydney
Phase 3 Active not recruiting